STOCK TITAN

Ionis Pharmaceuticals Inc - IONS STOCK NEWS

Welcome to our dedicated news page for Ionis Pharmaceuticals (Ticker: IONS), a resource for investors and traders seeking the latest updates and insights on Ionis Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ionis Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ionis Pharmaceuticals's position in the market.

Rhea-AI Summary
IONS: Ionis Pharmaceuticals, Inc. Announces Collaboration with Novartis for Next Generation Lp(a)-Targeting Therapy, Receives $60 Million Upfront Payment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.45%
Tags
none
-
Rhea-AI Summary
Ionis Pharmaceuticals completes enrollment in Phase 3 CARDIO-TTRansform study of eplontersen for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), with over 1,400 patients enrolled. Eplontersen is an investigational antisense medicine designed to inhibit transthyretin production and slow cardiomyopathy progression. Results expected in first half of 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.12%
Tags
clinical trial
-
Rhea-AI Summary
IONIS Pharmaceuticals, Inc. (IONS) expands collaboration with AstraZeneca to include exclusive rights for AstraZeneca to commercialize eplontersen in Latin America. AstraZeneca paid Ionis $20 million for the license. Ionis is eligible to receive up to $3.6 billion in milestone and other payments, with royalties in the range of low double-digit to mid-20s percentage depending on region. FDA accepted the New Drug Application for eplontersen for the treatment of ATTRv-PN with a PDUFA action date of Dec. 22, 2023. Eplontersen is also being evaluated for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.35%
Tags
none
Rhea-AI Summary
Ionis Pharmaceuticals, Inc. (IONS) to host live webcast to discuss second quarter 2023 financial results on August 9 at 11:30 a.m. Eastern Time. Access the webcast at https://ir.ionispharma.com/events-and-presentations/upcoming-events. Replay available for a limited time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.18%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.7%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Alcyone Therapeutics has received FDA approval to initiate a pivotal trial for its implantable medical device, ThecaFlex DRx System. The trial will evaluate the safety and performance of the device for the delivery of SPINRAZA in spinal muscular atrophy patients. The first stage of the trial is set to begin in summer 2023 with 10 patients, followed by enrollment of an additional 80 patients in a second stage starting in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.49%
Tags
clinical trial
-
Rhea-AI Summary
Alcyone Therapeutics has received FDA approval to initiate a pivotal trial for its implantable medical device, ThecaFlex DRx System. The trial will evaluate the safety and performance of the device for the delivery of SPINRAZA in spinal muscular atrophy patients. The first stage of the trial is set to begin in summer 2023 with 10 patients, followed by enrollment of an additional 80 patients in a second stage starting in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.66%
Tags
clinical trial
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.71%
Tags
none
Ionis Pharmaceuticals Inc

Nasdaq:IONS

IONS Rankings

IONS Stock Data

6.51B
144.53M
0.86%
101.03%
6.25%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Carlsbad

About IONS

ionis pharmaceuticals, inc., located in the north san diego county city of carlsbad, was founded in 1989 to create advanced, novel medicines to treat complex and challenging diseases. we are the pioneer in the discovery and development of antisense drugs with more than 1300 patents. ionis is a challenging, motivating and rewarding environment designed to foster innovation and scientific excellence. our founding goals have changed little in over 27 years and our success is a direct result of our outstanding employees. we are interested in bringing together individuals with different skill sets into this creative environment to be part of a productive team. join us and experience our unique culture while you develop and expand your career. for more information about ionis and to apply for an open position, please visit our website: www.ionispharma.com.